Medtech analyst chides Erin Brockovich's crusade against Bayer's birth control implant

November 7, 2013 by Arezu Sarvestani

GlobalData analyst Joseph Gregory says public advocate Erin Brockovich's patient safety claims against Bayer's Essure contraceptive implant are "inappropriate" and "unsubstantiated."

Analysts chide Erin Brockovich's crusade against Bayer's birth control implant

Healthcare giant Bayer (PINK:BAYRY) has another ally in the battle over its Essure contraceptive implant, with medical device analyst Joseph Gregory coming out against high-profile public advocate Erin Brockovich and her new interest in a growing outcry against the Essure procedure.

Gregory called Brockovich's claims against Essure "inappropriate" and "unsubstantiated," saying that the arguments against Essure fail to appreciate the less-than-1% apparent major adverse event rate and the thousands of patients helped by the device.

Sign up to get our free newsletters delivered right to your inbox.

"While the reported adverse cases are very serious and represent potential issues with the Essure device, or the procedure itself, they have to be considered in reference to how many patients in total have utilized and benefitted from this procedure," Gregory said in an official statement sent to "Although the adverse event profile may seem immensely large when highlighted, it isn't large enough to surpass 1%."